Furthermore, the unique genetical characteristics, with a lack of the typical Tp53 and KRAS mutations and properties of both ductal and acinar pancreatic carcinoma, that is described in the literature need to be taken into account when further analyzing the immune signaling of the DSl-6A/C1 PDAC tumor model [44]. This evidence concerns the gene TP53 and familial pancreatic carcinoma.